Category Archives: Public Policy

Latest From Public Policy

MassBio Releases Statement Following Cost Trends Hearings


MassBio issues this statement, following the Massachusetts’ Health Policy Commission’s (HPC) hearing earlier this week on the cost and value of health care cost trends. BIO stands with MassBio in our commitment to addressing the true cost and value of innovative medical therapies and their place within cost containment efforts across the entire healthcare system today. Innovation in biopharmaceuticals saves lives. It also saves money. Every reduced hospital stay, every surgery avoided, every inoculation can help reduce Read More >

Public Policy  |  Leave a comment  |  Email This Post
Tags: , , , ,

Five Oncologists Weigh in on Value Frameworks


Value Frameworks, which attempt to quantify the value of a medicine, have been a hot topic of late, given the recent proliferation of such frameworks and the ongoing debate about the cost and value of medicines. Last month, BIO CEO Jim Greenwood wrote about the critical importance of value frameworks being patient-centric and scientifically rigorous in their methodology. Today, writing in the Oncology Business Review, five oncologists joined the discussion, proposing five principles for value Read More >

Health, Public Policy  |  Leave a comment  |  Email This Post
Tags: , , ,

Patent Reform Needs to Address Trolling of All Stripes


As we enter the final days of the 114th Congress, it is regrettable that the unintended consequences of the PTO’s administrative patent challenge system known as Inter Partes Review, or IPR, continue to threaten innovative, intellectual property-reliant companies that are helping to drive this nation’s economic growth. It is vital that patent reform legislative efforts crack down on abuses of the IPR system and impose greater checks on the unfettered discretion of the PTO’s administrative Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , ,

What They’re Saying about the Medicare Part B Demo

health care, medicine

Back in March, CMS’s Center for Medicare and Medicaid Innovation (CMMI) proposed a sweeping demonstration project that would dramatically lower the rate at which many providers are reimbursed for medicines administered under Medicare Part B. Medicare Part B  covers drugs administered in a provider setting, and patients served under the program include those fighting diseases such as cancer, multiple sclerosis, macular degeneration, rheumatoid arthritis and primary immunodeficiency diseases – those most in need of the Read More >

Health, Public Policy  |  Leave a comment  |  Email This Post
Tags: , ,

NORD President: Congress must act now to help 15 million sick children


Writing in The Hill, National Organization for Rare Disorders (NORD) President and CEO Peter Saltonstall called upon Congress to act swiftly to maintain an important program encouraging research into treatments for rare pediatric diseases. The Rare Pediatric Priority Review Voucher (PRV) Program is set to expire at the end of the month, unless Congress reauthorizes it. Saltonstall writes: Developing therapies for people with rare diseases is incredibly difficult. Rare diseases are scientifically and medically complex, Read More >

Health, Public Policy  |  Leave a comment  |  Email This Post
Tags: , , , , , , , ,